A carregar...
Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome
Ravulizumab (Ultomiris(®)), a humanized monoclonal antibody that inhibits complement protein C5, is indicated for the treatment of atypical haemolytic uraemic syndrome (aHUS) in several countries, including the USA and those of the EU. Ravulizumab has been re-engineered from eculizumab to extend its...
Na minha lista:
| Publicado no: | Drugs |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer International Publishing
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8052220/ https://ncbi.nlm.nih.gov/pubmed/33738756 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-021-01481-6 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|